RETAVASE® (reteplase) is a recombinant plasminogen activator which catalyzes the cleavage of endogenous plasminogen to generate plasmin. Plasmin degrades the fibrin matrix of the thrombus, exerting its thrombolytic action.

Proven efficacy in acute STEMI1‑3

More patients achieved TIMI 2 or 3 flow at 90 minutes with RETAVASE® (reteplase) in the RAPID studies compared with alteplase1-3

Two clinical studies compared patency rates 90 minutes after treatment with RETAVASE or two different regimens of alteplase in patients with acute STEMI. Partial or complete flow (TIMI grades 2 or 3) and complete flow (TIMI grade 3) were reported.

Coronary artery patency: Angiographic results1

TIMI 2 or 3 TIMI 3 90 minute patency rates RAPID 2 RETAVASE (10 + 10 unit) n=157 83% 60% P value 0.03 0.01 Alteplase (100 mg over 1.5 hours) n=146 73% 45%
TIMI 2 or 3 TIMI 3 90 minute patency rates RAPID 1 RETAVASE (10 + 10 unit) n=142 85% 63% P value* 0.08 0.02 Alteplase (100 mg over 3 hours) n=145 77% 49%

*P value represents one of multiple dose comparisons.

  • The relationship between coronary artery patency and clinical efficacy has not been established1
  • Reocclusion rates for RETAVASE and alteplase were similar in both studies1-3

RAPID 2: Percentage of patients with total patency or complete reperfusion of infarct-related artery over time2

Complete reperfusion(TIMI grade 3) At hospital discharge5 to 14 days after therapy initiationn=128 Total patency(TIMI grades 2 and 3 combined) At 30 minutesn=55 At 60 minutesn=121 At 90 minutes†n=157 At 30 minutesn=55 At 60 minutesn=121 At 90 minutes†n=157 At hospital discharge5 to 14 days after therapy initiationn=128 RAPID 2 RETAVASE 10 + 10 unit 67.3% 81.8% 83.4% 89.1% 27.3% 51.2% 59.9% 75.0%

†Only the primary endpoint, the 90-minute assessment, was mandatory according to trial protocol.

RAPID 1: Percentage of patients with partial patency or complete reperfusion of infarct-related artery over time3

Complete reperfusion(TIMI grade 3) At hospital discharge5 to 14 days after therapy initiationn=123 Partial patency(TIMI grade 2) At 30 minutesn=48 At 60 minutesn=98 At 90 minutes†n=142 At 30 minutesn=48 At 60 minutesn=98 At 90 minutes†n=142 At hospital discharge5 to 14 days after therapy initiationn=123 RAPID 1 RETAVASE 10 + 10 unit 61.2% 77.6% 85.2% 95.1% 31.3% 51.0% 62.7% 87.8%

†Only the primary endpoint, the 90-minute assessment, was mandatory according to trial protocol.

Study design